These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 19690550

  • 1. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
    Gollins SW, Myint S, Susnerwala S, Haylock B, Wise M, Topham C, Samuel L, Swindell R, Morris J, Mason L, Levine E.
    Br J Cancer; 2009 Sep 15; 101(6):924-34. PubMed ID: 19690550
    [Abstract] [Full Text] [Related]

  • 2. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
    Gollins S, Sun Myint A, Haylock B, Wise M, Saunders M, Neupane R, Essapen S, Samuel L, Dougal M, Lloyd A, Morris J, Topham C, Susnerwala S.
    J Clin Oncol; 2011 Mar 10; 29(8):1042-9. PubMed ID: 21263095
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
    Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, Grobholz R, Willer A, Kähler G, Post S, Hofheinz RD.
    Br J Cancer; 2007 Mar 26; 96(6):912-7. PubMed ID: 17325705
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H.
    Cancer Chemother Pharmacol; 2012 Jul 26; 70(1):25-32. PubMed ID: 22610353
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.
    Ugidos L, Delgado S, Conill C, Ginés A, Gallego R, Ayuso JR, Miquel R, Tosca M, de Lacy A, Castells A, Maurel J.
    Invest New Drugs; 2009 Jun 26; 27(3):262-8. PubMed ID: 18923810
    [Abstract] [Full Text] [Related]

  • 9. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
    Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Lee KS, Yun T, Jeong SY, Choi HS, Lim SB, Chang HJ, Jung KH.
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):677-83. PubMed ID: 20888703
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG.
    Int J Radiat Oncol Biol Phys; 2015 Jan 01; 91(1):116-23. PubMed ID: 25446610
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
    Hofheinz RD, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kähler G, Dinter D, Grobholz R, Heeger S, Post S, Hochhaus A, Willeke F.
    Int J Radiat Oncol Biol Phys; 2006 Dec 01; 66(5):1384-90. PubMed ID: 16979839
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
    Malik I, Hussein F, Bush D, Alqaisi M, Bernal P, Byrd J, Garberoglio C.
    Am J Clin Oncol; 2010 Jun 01; 33(3):242-5. PubMed ID: 19806036
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
    Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-Tiefenbacher U, Müldner A, Hehlmann R, Post S, Hochhaus A, Willeke F.
    J Clin Oncol; 2005 Mar 01; 23(7):1350-7. PubMed ID: 15684318
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
    Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M.
    Br J Cancer; 2008 Apr 08; 98(7):1204-9. PubMed ID: 18349837
    [Abstract] [Full Text] [Related]

  • 18. Preoperative chemoradiation with capecitabine in locally advanced rectal cancer.
    de Bruin AF, Nuyttens JJ, Ferenschild FT, Planting AS, Verhoef C, de Wilt JH.
    Neth J Med; 2008 Feb 08; 66(2):71-6. PubMed ID: 18292610
    [Abstract] [Full Text] [Related]

  • 19. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
    Kennecke H, Berry S, Wong R, Zhou C, Tankel K, Easaw J, Rao S, Post J, Hay J.
    Eur J Cancer; 2012 Jan 08; 48(1):37-45. PubMed ID: 21664123
    [Abstract] [Full Text] [Related]

  • 20. Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART).
    Ricardi U, Racca P, Franco P, Munoz F, Fanchini L, Rondi N, Dongiovanni V, Gabriele P, Cassoni P, Ciuffreda L, Morino M, Filippi AR, Aglietta M, Bertetto O.
    Med Oncol; 2013 Jan 08; 30(2):581. PubMed ID: 23606239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.